Loading
A 12-gene test that combines gene activity with tumour size and lymph nodes to say whether hormone therapy alone is enough, and whether to continue it beyond five years.
EndoPredict (Sividon, acquired by Myriad Genetics in 2016) is CE-marked and validated in the ABCSG-6 and ABCSG-8 trial cohorts and in TransATAC, where EPclin identified a low-risk group with about 4% distant recurrence at 10 years on endocrine therapy alone and predicted late recurrence between years five and ten. NICE DG34 recommends it for guiding chemotherapy decisions in the NHS; it is offered in the US as a laboratory-developed test. Because it includes clinical variables, EPclin outperformed purely molecular scores in head-to-head comparisons on the TransATAC cohort.
RT-PCR of eight cancer genes and three reference genes gives a molecular score, combined with tumour size and nodal status into the EPclin score predicting 10-year distant recurrence.
1.EndoPredict slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EndoPredict" OR ABSTRACT:"EndoPredict") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EndoPredict, not a curated reading list.
Shares Myriad Genetics, RNA sequencing & expression profiling and the tag test.
Shares Myriad Genetics, HR-positive / HER2-negative breast cancer and the tag test.
Shares RNA sequencing & expression profiling, HR-positive / HER2-negative breast cancer and the tag test.
Shares Myriad Genetics and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares HR-positive / HER2-negative breast cancer and the tag test.
Shares RNA sequencing & expression profiling and the tag test.
Shares HR-positive / HER2-negative breast cancer and the tag test.